echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Haisco's Class 1 innovative drug HSK31679 first applied for clinical treatment of hypercholesterolemia

    Haisco's Class 1 innovative drug HSK31679 first applied for clinical treatment of hypercholesterolemia

    • Last Update: 2022-01-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Rubik's Cube Info

    On November 16, Haisco issued an announcement that the clinical application of the company's innovative drug HSK31679 tablets was accepted by the State Food and Drug Administration


    HSK31679 tablet is a highly selective thyroid hormone β receptor (THR-β) agonist independently developed by Haisco.


    Preclinical studies have shown that HSK31679 has good pharmacodynamic effects in hypercholesterolemia and NASH models, and has a good development prospect.


    Prior to this, the THR-β agonist ASC41 of Golly Pharmaceuticals has been approved for clinical use in the treatment of adult non-alcoholic steatohepatitis


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.